NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Impact of Lp299v on Vascular Function in Patients With PASC
Impact of Lp299v on Vascular Function in Patients With PASC

NCT05227170

Active Not RecruitingNA

Sponsor: Medical College of Wisconsin

Conditions: COVID-19

Interventions: Lactobacillus Plantarum 299v Freeze Dried Capsule, Freeze Dried Potato Starch Capsule

Countries: United States

Emerging data show that SARS-CoV-2 infection causes gut microbiome changes strongly associated with Post-Acute Sequelae of SARS-CoV-2 (PASC). The investigators and others have established that an orally ingested probiotic (Lactobacillus plantarum 299v, Lp299v) reduces circulating levels of cell-free mitochondrial DNA (cf-mtDNA), decreases toll-like receptor 9 (TLR9) activation \[and downstream interleukin (IL-6)\], and improves micro- and macrovascular (brachial artery) endothelial dysfunction \[as measured by flow-mediated dilation (FMD%)\] in humans. Recently published data also report impaired brachial FMD% and increased vascular stiffness post-SARS-CoV-2 infection. Based on these data, the investigators hypothesize that supplementation with Lp299v will attenuate SARS-CoV-2 associated endothelial dysfunction by reducing cf-mtDNA, TLR9 activation, and inflammation.

Eligibility overview

Sex: ALL

Age: 18 Years to 89 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Ages 18 to 89 years
* 30-180 days post-COVID-19 diagnosis
* PASC diagnosed based on symptom report/expert physician judgement

Exclusion Criteria:

* Antibiotics within four weeks of enrollment
* History of chronic diseases (renal insufficiency, liver dysfunction, cancer requiring systemic treatment within 3 years of enrollment)
* History of cognitive impairment/inability to follow study procedures
* Short gut syndrome, inflammatory bowel disease, or an ileostomy.
* Subjects currently taking Vitamin K antagonists such as coumadin or warfarin
* Pregnant at the time of screening
* Unstable coronary artery disease (new symptoms or event within 30 days of enrollment)
* Daily alcohol use (may interfere with Lp299v's action)
Locations (1)
  • Milwaukee, Wisconsin, United States